FDA Authorizes Oral Antiviral Treatment for COVID-19
In late December 2021, the U.S. Food & Drug Administration (FDA) issued an emergency use authorization for Pfizer’s PaxlovidTM and Merck’s molnupiravir for the treatment of mild-to-moderate coronavirus disease (COVID-19) for certain patients who are at high risk for progression to severe COVID-19, including hospitalization or death.
These treatments are available by prescription only, and the FDA recommends initiating them as soon as possible after diagnosis of COVID-19 and within five days of symptom onset. These prescriptions are covered by your pharmacy benefit through Express Scripts®.
If you receive a prescription, you can fill it at a participating pharmacy. Please call your pharmacy to ensure they have availability before you arrive. |